TY - JOUR
T1 - Interventional pharmacoeconomics
AU - Goldstein, Daniel A.
AU - Strohbehn, Garth W.
AU - Serritella, Anthony V.
AU - Hyman, David A.
AU - Lichter, Allen S.
AU - Ratain, Mark J.
N1 - Funding Information:
From the *Tel Aviv University, Tel Aviv; and †Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; ‡Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC; §Value in Cancer Care Consortium, Ann Arbor, MI; ||Section of Hematology/Oncology, University of Chicago Medicine, Chicago, IL; and ¶Georgetown University Law Center, Washington, DC. Conflicts of Interest and Source of Funding: G.W.S. is supported by the Richard and Debra Gonzalez Research Fellowship at the University of Chicago (established through philanthropy by Abbott Laboratories, Lake Bluff, IL). M.J.R. has served as a patent litigation consultant and expert witness on behalf of multiple generic pharmaceutical companies and has received consulting fees from Ascentage, Aptevo, Pneuma Respiratory, and Shionogi; clinical trial funding from AbbVie, Dicerna, and Genentech; and other support from BeiGene. For the remaining authors, none were declared. Reprints: Daniel A. Goldstein, MD, Davidoff Center, Rabin Medical Center, 39 Jabotinsky Street, Petach Tikvah, Israel. E‐mail: [email protected]. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 1528-9117
Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-label treatment regimens, based on pharmacologic rationale, with significant potential economic impact. The pharmacologic and clinical properties of many drugs allow for a variety of different strategies. We describe this approach of interventional pharmacoeconomics and provide multiple individual examples.
AB - The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-label treatment regimens, based on pharmacologic rationale, with significant potential economic impact. The pharmacologic and clinical properties of many drugs allow for a variety of different strategies. We describe this approach of interventional pharmacoeconomics and provide multiple individual examples.
KW - Clinical trials
KW - health policy
KW - pharmacoeconomics
KW - pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=85088885498&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088885498&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000461
DO - 10.1097/PPO.0000000000000461
M3 - Review article
C2 - 32732676
AN - SCOPUS:85088885498
SN - 1528-9117
VL - 26
SP - 330
EP - 334
JO - Cancer Journal (United States)
JF - Cancer Journal (United States)
IS - 4
ER -
